biostudies-literatureWei JNational Natural Science Foundation of China792-804https://www.ebi.ac.uk/biostudies/studies/S-EPMC8115146biostudies-literatureUnknown18(4)Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative refereCellular & molecular immunologyClinical development of CAR T cell therapy in China: 2020 update.PMC81151468183000231991171Wu ZZhu JGuo YBo JHan WWei JWang YZhang BfalseClinical development of CAR T cell therapy in China: 2020 update.Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative refere2021-01-01T00:00:00Z2021 Apr2026-05-09T09:48:18.107Z2025-04-03T21:33:30.039ZS-EPMC81151463299945510.1038/s41423-020-00555-x